{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:08:55Z","timestamp":1771934935318,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T00:00:00Z","timestamp":1671148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Alcohol-related cirrhosis is a frequent and difficult-to-treat disease. Despite the low hepatic metabolism of baclofen, data on its use in this subgroup are scarce. The French multicenter Observatory of patients treated with Baclofen for Alcohol DEpendence real-life cohort assessed: (a) prescription modalities of baclofen in liver units; (b) safety profile of baclofen; and (c) declared alcohol intake, biological markers of excessive alcohol intake and hepatic function at 12\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All consecutive patients with cirrhosis who received baclofen to reduce alcohol consumption or maintain abstinence were prospectively included. Psychosocial management was always associated. Clinical and biological data were collected every 3\u00a0months for 1\u00a0year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Between November 2013 and December 2016, 71 in- or outpatients were included from 10 liver units. Of the patients, 25% had ascites. After 12\u00a0months, 52 patients (73%) were still being followed, and 41 (57.7%) were still receiving baclofen at a mean dosage of 75\u00a0mg\/day (r30-210). The overall declared consumption decreased from 100.2 to 14.7\u00a0g\/day (P\u2009&amp;lt;\u20090.0001), and 29 patients (40.8%) reached abstinence. Significant improvement in the usual biomarkers of excessive alcohol intake (AST, GGT and MCV) and liver function (Prothrombin ratio (PTr), albumin levels) were observed. The usual side effects such as drowsiness were frequent (22%) but no serious adverse events (AEs) or overt encephalopathy related to baclofen was reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this 1-year follow-up series, baclofen was combined with psychosocial treatment in patients with cirrhosis and was well tolerated. This treatment was associated with a significant decrease in declared alcohol consumption as well as improvement in hepatic function.<\/jats:p><\/jats:sec>","DOI":"10.1093\/alcalc\/agac065","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:27:14Z","timestamp":1671269234000},"page":"117-124","source":"Crossref","is-referenced-by-count":8,"title":["Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study"],"prefix":"10.1093","volume":"58","author":[{"given":"Camille","family":"Barrault","sequence":"first","affiliation":[{"name":"Liver, Digestive Disease and Addiction Unit, CH Intercommunal , Cr\u00e9teil 83056 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaib","family":"Alqallaf","sequence":"additional","affiliation":[{"name":"Liver, Digestive Disease and Addiction Unit, CH Intercommunal , Cr\u00e9teil 83056 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hortensia","family":"Lison","sequence":"additional","affiliation":[{"name":"Liver and Digestive Diseases Nutrition and Addiction Department, GHPSO , Creil 60100 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lamote-Chaouche","sequence":"additional","affiliation":[{"name":"Addiction Unit, Liver, Digestive Disease and Addiction Unit, GHEF , Meaux 44730 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Bourcier","sequence":"additional","affiliation":[{"name":"Liver Unit, AP-HP, H\u00f4pitaux Universitaires Paris Seine Saint-Denis , Bobigny 93143 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Laugier","sequence":"additional","affiliation":[{"name":"Liver, Digestive Disease and Addiction Unit, CH Delafontaine, Saint Denis , Bobigny 93200 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Thevenot","sequence":"additional","affiliation":[{"name":"Liver Unit and Intensive Care Unit, H\u00f4pital Jean Minjoz , 25030 Besan\u00e7on Cedex , France"},{"name":"CIC-1431 INSERM, CHU de Besan\u00e7on , Besan\u00e7on 25030 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Labarriere","sequence":"additional","affiliation":[{"name":"Liver, Digestive Disease and Addiction Unit, CH R\u00e9gional , Orl\u00e9ans 75008 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Pierre","family":"Ripault","sequence":"additional","affiliation":[{"name":"Liver, Digestive Disease and Addiction Unit , CH, Narbonne 11108 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Le Gruyer","sequence":"additional","affiliation":[{"name":"Liver, Digestive Disease and Addiction Unit, CH Yves Le Foll , Saint Brieuc 22000 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Costentin","sequence":"additional","affiliation":[{"name":"Liver Unit, CHU Grenoble 38043, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Behar","sequence":"additional","affiliation":[{"name":"Liver, Digestive Disease and Addiction Unit, CH Intercommunal , Cr\u00e9teil 83056 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Hagege","sequence":"additional","affiliation":[{"name":"Liver, Digestive Disease and Addiction Unit, CH Intercommunal , Cr\u00e9teil 83056 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Jung","sequence":"additional","affiliation":[{"name":"CRC CH Intercommunal , Cr\u00e9teil 94010 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Cadranel","sequence":"additional","affiliation":[{"name":"Liver and Digestive Diseases Nutrition and Addiction Department, GHPSO , Creil 60100 , France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"The ANGH OBADE Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomized, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","article-title":"Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician","volume":"40","author":"Ameisen","year":"2005","journal-title":"Alcohol Alcohol"},{"key":"2023031122451937900_","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"2023031122451937900_","volume-title":"Une recommandation temporaire d\u2019utilisation (RTU) est accord\u00e9e pour le baclofene \u2013 Point d'information","author":"ANSM","year":"2014"},{"key":"2023031122451937900_","author":"ANSM","year":"2018"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/MEG.0000000000000922","article-title":"One year of baclofen in 100 patients with or without cirrhosis: a French real-life experience","volume":"29","author":"Barrault","year":"2017","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gut.15.1.52","article-title":"Studies in alcoholic liver disease in Britain. I. Clinical and pathological patterns related to natural history","volume":"15","author":"Brunt","year":"1974","journal-title":"Gut"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/pds.4635","article-title":"Risk of hospitalisation and death related to baclofen for alcohol use disorders: comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France","volume":"27","author":"Chaignot","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/fcp.12330","article-title":"Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients","volume":"32","author":"Chevillard","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"Management of alcohol-related liver disease","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","journal-title":"J Hepatol"},{"key":"2023031122451937900_","first-page":"e12892","article-title":"Is R(+)-Baclofen the best option for the future of Baclofen in alcohol dependence pharmacotherapy? Insights from the preclinical side [published online ahead of print, 2020 Mar 8]","volume":"26","author":"Echeverry-Alzate","year":"2020","journal-title":"Addict Biol"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/MEG.0000000000000714","article-title":"Randomized placebo-controlled study of baclofen in the treatment of muscle cramps in patients with liver cirrhosis","volume":"28","author":"Elfert","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamapsychiatry.2018.3079","article-title":"Evaluation of drinking risk levels as outcomes in alcohol pharmacotherapy trials: a secondary analysis of 3 randomized clinical trials","volume":"76","author":"Falk","year":"2019","journal-title":"JAMA Psychiat"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","article-title":"Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension","volume":"63","author":"Franchis","year":"2015","journal-title":"J Hepatol"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3109\/16066359.2015.1040003","article-title":"Tailored dose baclofen in patients with alcoholic liver disease: a case series with 2-year follow-up of hospitalization","volume":"23","author":"Heydtmann","year":"2015","journal-title":"Addict Res Theory"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2018.13","article-title":"Baclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomized, double-blind, placebo-controlled trial","volume":"212","author":"Morley","year":"2018","journal-title":"Br J Psychiatry"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/add.14373","article-title":"Moderation of baclofen response by a GABA(B) receptor polymorphism: results from the BacALD randomized controlled trial","volume":"113","author":"Morley","year":"2018","journal-title":"Addiction"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.alcohol.2016.12.005","article-title":"A prospective cohort study examining the effectiveness of baclofen in the maintenance of abstinence in alcohol use disorder patients attending a joint liver and alcohol treatment clinic","volume":"62","author":"Owens","year":"2017","journal-title":"Alcohol"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","article-title":"Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies","volume":"69","author":"Pimpin","year":"2018","journal-title":"JHepatol"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1465-3362.2009.00153.x","article-title":"Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis","volume":"29","author":"Rehm","year":"2010","journal-title":"Drug Alcohol Rev"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/agx030","article-title":"A randomized, placebo-controlled study of high-dose baclofen in alcohol-dependent patients\u2014the ALPADIR study","volume":"52","author":"Reynaud","year":"2017","journal-title":"Alcohol Alcohol"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/alcalc\/ags028","article-title":"Abstinence and 'low-risk' consumption 1 year after the initiation of high-dose baclofen: a retrospective study among 'high-risk' drinkers","volume":"47","author":"Rigal","year":"2012","journal-title":"Alcohol Alcohol"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/j.euroneuro.2015.05.008","article-title":"Baclofen for alcohol dependence: relationships between baclofen and alcohol dosing and the occurrence of major sedation","volume":"25","author":"Rolland","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"2023031122451937900_","first-page":"41e72","volume-title":"Measuring Alcohol Consumption: Psychosocial and Biochemical Methods","author":"Sobell","year":"1992"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/hep.30369","article-title":"EASL-AASLD Joint Meeting. Alcohol-related liver disease: areas of consensus, unmet needs and opportunities for further study","volume":"69","author":"Szabo","year":"2019","journal-title":"Hepatology"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/MEG.0000000000002304","article-title":"Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice","volume":"34","author":"Tyson","year":"2022","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2023031122451937900_","first-page":"193","volume-title":"International Guide for Monitoring Alcohol Consumption and Related Harm","author":"World Health Organization\u2014Department of Mental Health and Substance Dependence","year":"2000"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/hepr.12131","article-title":"Effect of abstinence from alcohol on survival of patients with alcoholic cirrhosis: a systematic review and meta-analysis","volume":"44","author":"Xie","year":"2014","journal-title":"Hepatol Res"},{"key":"2023031122451937900_","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/alcalc\/agu028","article-title":"Utilization of baclofen in maintenance of alcohol abstinence in patients with alcohol dependence and alcoholic hepatitis with or without cirrhosis","volume":"49","author":"Yamini","year":"2014","journal-title":"Alcohol Alcohol"}],"container-title":["Alcohol and Alcoholism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/58\/2\/117\/49498669\/agac065.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/alcalc\/article-pdf\/58\/2\/117\/49498669\/agac065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T03:04:52Z","timestamp":1678590292000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/alcalc\/article\/58\/2\/117\/6918726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,16]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,12,16]]},"published-print":{"date-parts":[[2023,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/alcalc\/agac065","relation":{},"ISSN":["0735-0414","1464-3502"],"issn-type":[{"value":"0735-0414","type":"print"},{"value":"1464-3502","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3]]},"published":{"date-parts":[[2022,12,16]]}}}